Methods for cancer therapy using isolated NTB-A ectodomain polypeptides
US11530251B2 · kind B2 · utility
0Cited by
12References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2019 |
| Grant date | Dec 20, 2022 |
| Priority date | — |
| Expiry date | Oct 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/998
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.